Plain-English translation of NCT04803994 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether a medication combination called plus works better than a standard procedure called TACE (transarterial chemoembolization) for treating intermediate-stage liver cancer. About 434 patients will be enrolled across 60 sites in 10 countries. The study will compare how well each treatment works, how safe it is, and how it affects your quality of life and liver function over time.
Currently, TACE is a standard treatment for intermediate-stage liver cancer, but doctors want to know whether this newer medication combination might work better or be easier for patients to tolerate. This trial will help answer that question and potentially give patients more treatment options.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to receive either the medication combination (given as intravenous infusions every 3 weeks for up to 24 months) or the TACE procedure (initial treatment, possibly a second treatment 8 weeks later, then additional procedures as needed). You will have regular clinic visits for blood tests, imaging scans, and assessments of how you're feeling. The study team will monitor you for side effects and how well the treatment is working throughout the 24-month period or until treatment is no longer helping you.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Austria